Results 21 to 30 of about 14,165 (152)

Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma

BMC Medicine, 2022
Background Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC).
Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li, Zhiyuan Zhang, Rong Zhou   +11 more
doaj   +1 more source

Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling

Current Issues in Molecular Biology
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor and a commonly used antitumor drug. Many cancers are susceptible to palbociclib resistance, however, the underlying metabolism mechanism and extent of resistance to palbociclib are unknown.
Lulu Yang, Yajun Yue, Zhendong Wang, You Jiang, Zhichao Xue, Yongzhuo Zhang   +5 more
doaj   +1 more source

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Journal of Global Oncology, 2017
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a ...
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro   +14 more
doaj   +1 more source

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older

Frontiers in Oncology, 2023
BackgroundElderly patients are generally underrepresented in oncology clinical trials; therefore, real-world data are needed to inform clinical management of elderly patients with hormone receptor–positive/human epidermal growth factor receptor 2 ...
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo   +6 more
doaj   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Journal of Experimental & Clinical Cancer Research, 2018
Background Cell cycle regulators have gain attention as potential targets for anticancer therapy. Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which coordinate the G1-S transition.
Daniele Cretella, Andrea Ravelli, Claudia Fumarola, Silvia La Monica, Graziana Digiacomo, Andrea Cavazzoni, Roberta Alfieri, Alessandra Biondi, Daniele Generali, Mara Bonelli, Pier Giorgio Petronini   +10 more
doaj   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval

Breast Cancer Research, 2018
Background Rapidly evolving understanding of cancer biology has presented novel opportunities to translate that understanding into clinically relevant therapy.
J. K. Kish, M. A. Ward, D. Garofalo, H. V. Ahmed, L. McRoy, J. Laney, G. Zanotti, J. Braverman, H. Yu, B. A. Feinberg   +9 more
doaj   +1 more source

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

PLoS ONE, 2022
Inducing senescence in cancer cells is emerging as a new therapeutic strategy. In order to find ways to enhance senescence induction by palbociclib, a CDK4/6 inhibitor approved for treatment of metastatic breast cancer, we performed functional genetic ...
Ziva Pogacar, Jackie L Johnson, Lenno Krenning, Giulia De Conti, Fleur Jochems, Cor Lieftink, Arno Velds, Leyma Wardak, Kelvin Groot, Arnout Schepers, Liqin Wang, Ji-Ying Song, Marieke van de Ven, Olaf van Tellingen, Rene H Medema, Roderick L Beijersbergen, Rene Bernards, Rodrigo Leite de Oliveira   +17 more
doaj   +1 more source

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models

Molecular Therapy: Nucleic Acids, 2022
Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT ...
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini   +9 more
doaj   +1 more source